Stent News and Research

RSS

A stent is a small mesh tube that’s used to treat narrowed or weakened arteries in the body.

You may have a stent placed in an artery as part of a procedure called angioplasty (AN-jee-oh-plas-tee). Angioplasty can restore blood flow through narrowed or blocked arteries. Stents help prevent arteries from becoming narrowed or blocked again in the months or years after treatment with angioplasty. You may also have a stent placed in a weakened artery to improve blood flow and to help prevent the artery from bursting.

Stents are usually made of metal mesh, but sometimes they’re made of fabric. Fabric stents, also called stent grafts, are used in larger arteries. Some stents are coated with medicines that are slowly and continuously released into the artery. These medicines help prevent the artery from becoming blocked again.

SIR and 41 international societies issue first global statement defining interventional radiology

The Society of Interventional Radiology, with the support of 41 international societies representing 10,000 interventional radiology doctors, has issued the first global statement defining interventional radiology-one designed to benefit medical treatment for individuals. The statement addresses the evolution, impact and future direction of this minimally invasive specialty, emphasizing the worldwide availability of this specialized medical care.

8 Jul 2010

St. Jude Medical acquires LightLab Imaging

St. Jude Medical, Inc., a global medical device company, today completed the previously announced acquisition of LightLab Imaging, Inc. for approximately $90 million in cash.

7 Jul 2010

Gore receives European CE Mark approval for 25 cm GORE VIABAHN Endoprosthesis

W. L. Gore & Associates today announced that it has received European CE Mark approval for the 25 cm GORE VIABAHN Endoprosthesis with PROPATEN Bioactive Surface. The new 25 cm GORE VIABAHN Endoprosthesis with PROPATEN Bioactive Surface is the longest length stent-graft available, designed to cover more of the lesion in the Superficial Femoral Artery potentially reducing the need for multiple devices.

1 Jul 2010

Lack of reimbursements limit drug-eluting stent market across Latin America

According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, despite the rising popularity of drug-eluting stents (DES) across Latin America, bare-metal stents (BMS) will continue to represent a significant portion of the overall coronary stent market through 2014. This trend is especially evident in Brazil, where the public healthcare system does not provide any reimbursement for DES procedures.

30 Jun 2010

Daiichi Sankyo, Eli Lilly respond to ACCF/AHA clinical alert on FDA's clopidogrel boxed warning

Daiichi Sankyo, Inc. and Eli Lilly and Company appreciate the availability of a "Clinical Alert" from the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) in response to the FDA's Boxed Warning about Plavix® (clopidogrel), and commend the leading cardiovascular medical societies for providing perspective on the importance of genetic make-up and the variability in response of certain oral anti-platelet (OAP) therapy for patients with acute coronary syndrome (ACS) who are managed with angioplasty and stenting (known as PCI).

29 Jun 2010

IDEV enters exclusive distribution agreement with TriReme for GliderXtreme PTA balloon catheter

IDEV Technologies, Incorporated (IDEV), an emerging leader in the development and marketing of minimally invasive medical technologies, today announced that it has entered into an exclusive distribution agreement covering the U.S. and Germany for TriReme Medical, Inc.'s (TriReme) GliderXtreme™ PTA balloon catheter, an advanced product with specific features for the expanding Peripheral Arterial Disease (PAD) market.

24 Jun 2010

Tryton announces first three implants of Side Branch Stent System in Israel

Tryton Medical, Inc., the leading developer of stents designed to definitively treat bifurcation lesions, announced that the company's TRYTON Side Branch Stent™ System has been used in three cases in Israel for the first time.

24 Jun 2010

OrbusNeich's Genous Bio-engineered R stent shows safety for percutaneous treatment of coronary artery stenosis

OrbusNeich today announced that six-month clinical follow-up data show the safety and efficacy of the combination of pre-dilatation with a paclitaxel drug-eluting balloon (Sequent Please®, B.Braun) followed by implantation of the company's Genous Bio-engineered R stent for the percutaneous treatment of coronary artery stenosis.

22 Jun 2010

PAS technique to predict how blood platelets respond to complex conditions found during heart attack

A team of bioengineers from the University of Pennsylvania Institute for Medicine and Engineering have trained a computer neural network model to accurately predict how blood platelets would respond to complex conditions found during a heart attack or stroke.

21 Jun 2010

Cook Medical files for PMA of Zilver PTX Drug-Eluting Peripheral Stent with FDA

Cook Medical has submitted its Pre-Market Approval (PMA) application to the U.S. Food and Drug Administration (FDA) for the company's unique polymer-free Zilver® PTX® Drug-Eluting Peripheral Stent. Intended for use in patients with peripheral arterial disease (PAD) in the superficial femoral artery (SFA), Zilver PTX is a self-expanding, highly durable nitinol stent that uses a proprietary, polymer-free technology to deliver a locally therapeutic dose of paclitaxel, an antiproliferative drug, to the target lesion.

11 Jun 2010

FDA approves Endologix's expanded Powerlink stent graft product line

Endologix, Inc., developer of minimally invasive treatments for aortic disorders, announced today that it has received U.S. Food and Drug Administration (FDA) approval for its expanded offering of Powerlink® stent graft products. The approval covers 31 new sizes of Powerlink® main body bifurcated, proximal extension, and limb extension stent grafts that increase the system's addressable patient population by 5% to 10%.

10 Jun 2010

Boston Scientific's TAXUS Element Paclitaxel-Eluting Coronary Stent System launched in Europe

Boston Scientific Corporation today announced the market launch and first implants of its TAXUS® Element™ Paclitaxel-Eluting Coronary Stent System in the European Union and other CE Mark countries. The TAXUS Element Stent System is the Company's third-generation drug-eluting stent (DES) technology and incorporates a platinum chromium alloy with an innovative stent design and an advanced catheter delivery system. It received CE Mark approval last month, which included a specific indication for the treatment of diabetic patients.

10 Jun 2010

Spectranetics plans multi-center, randomized clinical trial program for in-stent restenosis

The Spectranetics Corporation today announced its clinical trial plans related to the treatment of in-stent restenosis (ISR) in arteries above the knee, which remains a major unsolved medical problem. There is no device currently cleared or approved by the FDA to treat ISR.

10 Jun 2010

DSM announces agreements with Biomedical Structures, Cortland and Secant Medical

DSM, which created and manufactures Dyneema Purity, the world's strongest Medical grade fiber, today announced agreements with Biomedical Structures, Cortland Company and Secant Medical. These companies' experience in processing Dyneema Purity fiber in biomedical textile structures offers medical device companies the ability to use various constructions of Dyneema Purity, including the recently launched Dyneema Purity BLUE, in commercial medical devices.

9 Jun 2010

Researchers find LEB or EV demonstrates faster rate of healing for larger wounds

Researchers from Georgetown University Hospital in Washington, DC have found that wound healing after lower extremity bypass or endovascular revascularization demonstrated a more complete and faster rate of healing for larger wounds of more than 2 cm after open bypass. Findings will be presented at the 64th Vascular Annual Meeting presented by the Society for Vascular Surgery, June 10 in Boston.

8 Jun 2010

US Court lifts stay on Cook's endovascular technology patent infringement case against Endologix

The United States District Court, Southern District of Indiana, has ruled in favor of Cook Incorporated in its decision to lift the stay on Cook's patent infringement case against Endologix, Inc.. With this ruling, the case, filed by Cook on October 6, 2009, will now proceed. The complaint claims infringement by Endologix of two Cook patents for endovascular technologies, one of Cook's leading technology portfolios.

8 Jun 2010

Endologix named as Orange County's Outstanding Company in Medical Technology

Endologix, Inc., developer of minimally invasive treatments for aortic disorders, announced today that TechAmerica has named Endologix as Orange County's Outstanding Company in Medical Technology. The award was presented to Endologix at the 17th Annual TechAmerica High-Tech Innovation Awards on June 2, 2010 in Irvine, CA.

5 Jun 2010

Patients at greatest risk of post-PCI bleeding least likely to receive bleeding avoidance strategies

In a study that included data from more than 1.5 million patients, use of vascular closure devices and the anticoagulant bivalirudin were associated with significantly lower bleeding rates for patients following a percutaneous coronary intervention (PCI; procedures such as balloon angioplasty or stent placement used to open narrowed coronary arteries), according to a study in the June 2 issue of JAMA. The researchers also found that patients who may benefit most from these treatments, those at greatest risk of bleeding, were least likely to receive them.

2 Jun 2010

Cook Medical's Resonance Metallic Ureteral Stent demonstrates long-term success in 29-month clinical study

A 29-month clinical study demonstrated the long-term success of Cook Medical's Resonance® Metallic Ureteral Stent in providing drainage for patients with both benign and malignant upper urinary tract obstructions, according to results presented today at the 2010 Annual Meeting of the American Urological Association (AUA). The findings suggest that metallic stents provide adequate drainage and can be maintained in situ for 12 months without significant encrustation.

2 Jun 2010

Texas Heart Institute at St. Luke's Episcopal Hospital performs 1000th carotid artery stent procedure

The Texas Heart Institute (THI) at St. Luke's Episcopal Hospital has announced another major milestone in improved patient care, after performing its 1000th carotid artery stent procedure. Carotid artery stenting (CAS) has emerged as a less invasive treatment for stroke-causing blockages in the carotid artery, meaning patients generally have fewer risks for complications, shorter hospital stays and recovery times and less expense.

2 Jun 2010

Stent News and Research

Further Reading

SIR and 41 international societies issue first global statement defining interventional radiology

St. Jude Medical acquires LightLab Imaging

Gore receives European CE Mark approval for 25 cm GORE VIABAHN Endoprosthesis

Lack of reimbursements limit drug-eluting stent market across Latin America

Daiichi Sankyo, Eli Lilly respond to ACCF/AHA clinical alert on FDA's clopidogrel boxed warning

IDEV enters exclusive distribution agreement with TriReme for GliderXtreme PTA balloon catheter

Tryton announces first three implants of Side Branch Stent System in Israel

OrbusNeich's Genous Bio-engineered R stent shows safety for percutaneous treatment of coronary artery stenosis

PAS technique to predict how blood platelets respond to complex conditions found during heart attack

Cook Medical files for PMA of Zilver PTX Drug-Eluting Peripheral Stent with FDA

FDA approves Endologix's expanded Powerlink stent graft product line

Boston Scientific's TAXUS Element Paclitaxel-Eluting Coronary Stent System launched in Europe

Spectranetics plans multi-center, randomized clinical trial program for in-stent restenosis

DSM announces agreements with Biomedical Structures, Cortland and Secant Medical

Researchers find LEB or EV demonstrates faster rate of healing for larger wounds

US Court lifts stay on Cook's endovascular technology patent infringement case against Endologix

Endologix named as Orange County's Outstanding Company in Medical Technology

Patients at greatest risk of post-PCI bleeding least likely to receive bleeding avoidance strategies

Cook Medical's Resonance Metallic Ureteral Stent demonstrates long-term success in 29-month clinical study

Texas Heart Institute at St. Luke's Episcopal Hospital performs 1000th carotid artery stent procedure

Industry Focus eBook - Forensics & toxicology (2nd edition) eBook

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring

Latest News